-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 15th, Sichuan Huiyu Pharmaceutical submitted a listing application for Fulvestrant injection, and Hausen’s application for generic listing of 4 types of generic products has also entered the approval stage recently.
Imitation is extremely intense
.
Imitation is extremely intense
.
Figure 1: The latest product information declared by Huiyu
Source: CDE official website
Figure 2: Hausen's product registration progress
Source: NMPA official website
Fulvestrant is a downregulator of the estrogen receptor (ER), which can block the binding of estrogen and ER.
It is clinically used for relapses after or during the treatment of anti-estrogen adjuvant therapy or progress in anti-estrogen therapy Of postmenopausal ER+ locally advanced or metastatic breast cancer
.
In 2002, AstraZeneca's original research drug was approved by the FDA for marketing.
In 2018, global sales exceeded US$1 billion
.
It is clinically used for relapses after or during the treatment of anti-estrogen adjuvant therapy or progress in anti-estrogen therapy Of postmenopausal ER+ locally advanced or metastatic breast cancer
.
In 2002, AstraZeneca's original research drug was approved by the FDA for marketing.
In 2018, global sales exceeded US$1 billion
.
AstraZeneca's name drugs approved in 2010 to enter the Chinese market, in 2017 to enter the health insurance directory of negotiations, is a version of the 2020 national health insurance directory B varieties, in 2020 China's urban public hospitals , county-level public hospitals, community centers and city The terminal sales of township health centers (referred to as Chinese public medical institutions) exceeded 400 million yuan
.
.
Figure 3: Enterprise competitive landscape of 2021H1 Fulvestrant injection
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
CP Tianqing Pharmaceutical Group submitted 4 types of generic listing applications in 2019, and was approved for the first imitation + first review in August 2020.
The market share of 2021H1 in China's public medical institutions has exceeded 10%.
Domestic high-end imitations The potential of pharmaceuticals is exploding rapidly
.
The market share of 2021H1 in China's public medical institutions has exceeded 10%.
Domestic high-end imitations The potential of pharmaceuticals is exploding rapidly
.
Hausen and Hangzhou Jiuyuan Genetic Engineering submitted 4 types of imitation listing applications in March and October 2020 respectively.
At present, Hausen has entered the approval stage, and the acceptance number of Hangzhou Jiuyuan Genetic Engineering is under review and approval
.
On November 15, 2021, Sichuan Huiyu Pharmaceutical, which has made great achievements in the field of high-end injections in recent years, also joined the market battle
.
At present, Hausen has entered the approval stage, and the acceptance number of Hangzhou Jiuyuan Genetic Engineering is under review and approval
.
On November 15, 2021, Sichuan Huiyu Pharmaceutical, which has made great achievements in the field of high-end injections in recent years, also joined the market battle
.
Source: NMPA official website, CDE official website, Minet database
The review data statistics are as of November 15.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
On November 15th, Sichuan Huiyu Pharmaceutical submitted a listing application for Fulvestrant injection, and Hausen’s application for generic listing of 4 types of generic products has also entered the approval stage recently.
Imitation is extremely intense
.
Imitation is extremely intense
.
Figure 1: The latest product information declared by Huiyu
Source: CDE official website
Figure 2: Hausen's product registration progress
Source: NMPA official website
Fulvestrant is a downregulator of the estrogen receptor (ER), which can block the binding of estrogen and ER.
It is clinically used for relapses after or during the treatment of anti-estrogen adjuvant therapy or progress in anti-estrogen therapy Of postmenopausal ER+ locally advanced or metastatic breast cancer
.
In 2002, AstraZeneca's original research drug was approved by the FDA for marketing.
In 2018, global sales exceeded US$1 billion
.
It is clinically used for relapses after or during the treatment of anti-estrogen adjuvant therapy or progress in anti-estrogen therapy Of postmenopausal ER+ locally advanced or metastatic breast cancer
.
In 2002, AstraZeneca's original research drug was approved by the FDA for marketing.
In 2018, global sales exceeded US$1 billion
.
AstraZeneca's name drugs approved in 2010 to enter the Chinese market, in 2017 to enter the health insurance directory of negotiations, is a version of the 2020 national health insurance directory B varieties, in 2020 China's urban public hospitals , county-level public hospitals, community centers and city The terminal sales of township health centers (referred to as Chinese public medical institutions) exceeded 400 million yuan
.
.
Figure 3: Enterprise competitive landscape of 2021H1 Fulvestrant injection
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
CP Tianqing Pharmaceutical Group submitted 4 types of generic listing applications in 2019, and was approved for the first imitation + first review in August 2020.
The market share of 2021H1 in China's public medical institutions has exceeded 10%.
Domestic high-end imitations The potential of pharmaceuticals is exploding rapidly
.
The market share of 2021H1 in China's public medical institutions has exceeded 10%.
Domestic high-end imitations The potential of pharmaceuticals is exploding rapidly
.
Hausen and Hangzhou Jiuyuan Genetic Engineering submitted 4 types of imitation listing applications in March and October 2020 respectively.
At present, Hausen has entered the approval stage, and the acceptance number of Hangzhou Jiuyuan Genetic Engineering is under review and approval
.
On November 15, 2021, Sichuan Huiyu Pharmaceutical, which has made great achievements in the field of high-end injections in recent years, also joined the market battle
.
At present, Hausen has entered the approval stage, and the acceptance number of Hangzhou Jiuyuan Genetic Engineering is under review and approval
.
On November 15, 2021, Sichuan Huiyu Pharmaceutical, which has made great achievements in the field of high-end injections in recent years, also joined the market battle
.
Source: NMPA official website, CDE official website, Minet database
The review data statistics are as of November 15.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
On November 15th, Sichuan Huiyu Pharmaceutical submitted a listing application for Fulvestrant injection, and Hausen’s application for generic listing of 4 types of generic products has also entered the approval stage recently.
Imitation is extremely intense
.
Imitation is extremely intense
.
Figure 1: The latest product information declared by Huiyu
Source: CDE official website
Figure 2: Hausen's product registration progress
Source: NMPA official website
Fulvestrant is a downregulator of the estrogen receptor (ER), which can block the binding of estrogen and ER.
It is clinically used for relapses after or during the treatment of anti-estrogen adjuvant therapy or progress in anti-estrogen therapy Of postmenopausal ER+ locally advanced or metastatic breast cancer
.
In 2002, AstraZeneca's original research drug was approved by the FDA for marketing.
In 2018, global sales exceeded US$1 billion
.
It is clinically used for relapses after or during the treatment of anti-estrogen adjuvant therapy or progress in anti-estrogen therapy Of postmenopausal ER+ locally advanced or metastatic breast cancer
.
In 2002, AstraZeneca's original research drug was approved by the FDA for marketing.
In 2018, global sales exceeded US$1 billion
.
AstraZeneca's name drugs approved in 2010 to enter the Chinese market, in 2017 to enter the health insurance directory of negotiations, is a version of the 2020 national health insurance directory B varieties, in 2020 China's urban public hospitals , county-level public hospitals, community centers and city The terminal sales of township health centers (referred to as Chinese public medical institutions) exceeded 400 million yuan
.
Hospital hospital hospital.
Figure 3: Enterprise competitive landscape of 2021H1 Fulvestrant injection
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
CP Tianqing Pharmaceutical Group submitted 4 types of generic listing applications in 2019, and was approved for the first imitation + first review in August 2020.
The market share of 2021H1 in China's public medical institutions has exceeded 10%.
Domestic high-end imitations The potential of pharmaceuticals is exploding rapidly
.
The market share of 2021H1 in China's public medical institutions has exceeded 10%.
Domestic high-end imitations The potential of pharmaceuticals is exploding rapidly
.
Hausen and Hangzhou Jiuyuan Genetic Engineering submitted 4 types of imitation listing applications in March and October 2020 respectively.
At present, Hausen has entered the approval stage, and the acceptance number of Hangzhou Jiuyuan Genetic Engineering is under review and approval
.
On November 15, 2021, Sichuan Huiyu Pharmaceutical, which has made great achievements in the field of high-end injections in recent years, also joined the market battle
.
At present, Hausen has entered the approval stage, and the acceptance number of Hangzhou Jiuyuan Genetic Engineering is under review and approval
.
On November 15, 2021, Sichuan Huiyu Pharmaceutical, which has made great achievements in the field of high-end injections in recent years, also joined the market battle
.
Source: NMPA official website, CDE official website, Minet database
The review data statistics are as of November 15.
If there are any errors or omissions, please correct me
.
If there are any errors or omissions, please correct me
.
